Irritable Bowel Syndrome: Ketotife

Completed

• Conditions: Irritable bowel syndrome (IBS); Digestive System; Irritable bowel syndrome

• Registration Number: ISRCTN22504486
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-08-04
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Fulfilling Rome II criteria of Irritable Bowel Syndrome (IBS)
2. 18 to 65 years of age
3. No other organic abnormalities explaining the complaints

Exclusion Criteria

1. Severe comorbidity
2. Use of sedatives, hypnotics or antihistamines
3. Pregnancy/lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effect of the mast cell-stabiliser ketotifen on the rectal sensitivity in IBS.

Secondary Outcome Measures

Name	Time	Method
1. The effect of the mast cell-stabiliser ketotifen on inflammation in rectal biopsy specimen<br>2. The effect of ketotifen on IBS-symptoms